针刺治疗中重度持续性变应性鼻炎的疗效与安全性:临床随机对照试验

注册号:

Registration number:

ChiCTR2500095634 

最近更新日期:

Date of Last Refreshed on:

2025-01-09 16:38:08 

注册时间:

Date of Registration:

2025-01-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

针刺治疗中重度持续性变应性鼻炎的疗效与安全性:临床随机对照试验

Public title:

Efficacy and safety of acupuncture in the treatment of moderate-to-severe persistent allergic rhinitis: a randomized controlled clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗中重度持续性变应性鼻炎的疗效与安全性:临床随机对照试验

Scientific title:

Efficacy and safety of acupuncture in the treatment of moderate-to-severe persistent allergic rhinitis: a randomized controlled clinical trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

鄢晓婷 

研究负责人:

郭斌 

Applicant:

Yan Xiaoting 

Study leader:

Guo Bin 

申请注册联系人电话:

Applicant telephone:

+86 152 9791 6315

研究负责人电话:

Study leader's
telephone:

+86 186 3549 0771

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yan_xt2021@163.com

研究负责人电子邮件:

Study leader's E-mail:

guo12200055@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东广州番禺区外环东路232号

研究负责人通讯地址:

宁夏银川市胜利街1160号

Applicant address:

232 Waihuan Road East, Guangzhou, Guangdong, China

Study leader's address:

1160 Shengli Street, Yinchuan City, Ningxia

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学

Applicant's institution:

Guangzhou University of Chinese Medicine

研究负责人所在单位:

宁夏医科大学

Affiliation of the Leader:

Ningxia Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-075

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁夏医科大学医学伦理审查委员会

Name of the ethic committee:

Medical Ethics Review Committee of Ningxia Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-19 00:00:00

伦理委员会联系人:

韩怀钦

Contact Name of the ethic committee:

Han Huaiqin

伦理委员会联系地址:

宁夏银川市胜利街1160号

Contact Address of the ethic committee:

1160 Shengli Street, Yinchuan City, Ningxia

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 139 9547 2886

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁夏医科大学

Primary sponsor:

Ningxia Medical University

研究实施负责(组长)单位地址:

宁夏银川市胜利街1160号

Primary sponsor's address:

1160 Shengli Street, Yinchuan City, Ningxia

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

宁夏回族自治区

市(区县):

银川市

Country:

China

Province:

Ningxia Hui Autonomous Region

City:

Yinchuan

单位(医院):

宁夏医科大学

具体地址:

宁夏银川市胜利街1160号

Institution
hospital:

Ningxia Medical University

Address:

1160 Shengli Street, Yinchuan City, Ningxia

经费或物资来源:

宁夏回族自治区科学技术厅

Source(s) of funding:

Department of Science and Technology of Ningxia Hui Autonomous Region

研究疾病:

变应性鼻炎  

Target disease:

allergic rhinitis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价不同针灸方法对变应性鼻炎的的疗效及安全性,通过与常规治疗方案进行对比,分析相关结局指标,为临床进一步优化治疗方案提供支持。  

Objectives of Study:

To evaluate the efficacy and safety of different acupuncture and moxibustion methods for allergic rhinitis, and to analyze the relevant outcome indicators by comparing with conventional treatment schemes, so as to provide support for further optimization of clinical treatment schemes.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)14日之内曾患有呼吸道感染或急性副鼻窦炎者;胸部X片出现炎症现象者; (2)有慢性副鼻窦炎病史、或经副鼻窦X光检查发现患有慢性副鼻窦炎者; (3)鼻腔有器质性病变或行鼻腔手术者; (4)合并其他如哮喘等发作性呼吸系统疾病者;或合并严重肝肾功能不良、心脑血管疾病、精神系统疾病以及患有其他严重疾病不能接受治疗者; (5)14日之内曾服用过H1-抗组胺药、类固醇及抗组胺制剂、减充血剂(作用于鼻、口、眼部位)、皮质类固醇、抗生素等药物者; (6)最近一年内曾接受过特定免疫疗法或长期持续激素治疗的患者; (7)14日内曾接受针、埋线、灸、罐、鼻内中药吸入等中医学范围内的物理疗法者; (8)妊娠、哺乳期或备孕期妇女; (9)同时参与其他临床试验者; (10)临床研究者认为参与临床研究的被试者不能配合治疗者。

Exclusion criteria:

(1) Those who have suffered from respiratory tract infection or acute sinusitis within 14 days; Inflammation on chest X-ray; (2) Those who have a history of chronic paranasal sinusitis or are found to have chronic paranasal sinusitis by X-ray examination of paranasal sinuses; (3) organic lesions in the nasal cavity or nasal surgery; (4) Patients with other paroxysmal respiratory diseases such as asthma; Or complicated with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases, mental system diseases and other serious diseases that cannot be treated; (5) Those who have taken H1- antihistamines, steroids and antihistamines, decongestants (acting on nose, mouth and eyes), corticosteroids and antibiotics within 14 days; (6) Patients who have received specific immunotherapy or long-term continuous hormone therapy in the last year; (7) Those who have received physical therapy within the scope of traditional Chinese medicine within 14 days, such as acupuncture, catgut embedding, moxibustion, cupping and nasal inhalation of traditional Chinese medicine; (8) pregnant, lactating or pregnant women; (9) Participants in other clinical trials at the same time; (10) Clinical researchers believe that the subjects participating in clinical research cannot cooperate with the therapists.

研究实施时间:

Study execute time:

From 2024-09-23 00:00:00 To 2026-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-20 00:00:00 To 2026-03-31 00:00:00

干预措施:

Interventions:

组别:

针刺组

样本量:

132

Group:

acupuncture group

Sample size:

干预措施:

针刺

干预措施代码:

Intervention:

acupuncture

Intervention code:

组别:

假针刺组

样本量:

132

Group:

sham acupuncture group

Sample size:

干预措施:

假针刺

干预措施代码:

Intervention:

sham acupuncture

Intervention code:

组别:

穴位埋线组

样本量:

132

Group:

Acupoint catgut embedding group

Sample size:

干预措施:

穴位埋线

干预措施代码:

Intervention:

Acupoint catgut embedding

Intervention code:

组别:

假穴位埋线

样本量:

132

Group:

Sham Acupoint catgut embedding group

Sample size:

干预措施:

假穴位埋线

干预措施代码:

Intervention:

Sham Acupoint catgut embedding

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

宁夏回族自治区 

市(区县):

银川 

Country:

China

Province:

Ningxia Hui Autonomous Region

City:

Yinchuan

单位(医院):

宁夏回族自治区中医医院暨中医研究院 

单位级别:

三甲 

Institution
hospital:

Ningxia Hui Autonomous Region Hospital and Academy of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China

Province:

Guangdong Province

City:

Guangzhou

单位(医院):

中山大学附属第三医院 

单位级别:

三甲 

Institution
hospital:

The Third Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山西省 

市(区县):

太原 

Country:

China

Province:

Shanxi Province

City:

Taiyuan

单位(医院):

山西中医药大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Shanxi University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

鼻炎控制测试

指标类型:

主要指标

Outcome:

The Rhinitis Control Assessment Test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鼻结膜炎生存质量量表

指标类型:

次要指标

Outcome:

RQLQ scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

过敏性鼻炎症状评分

指标类型:

次要指标

Outcome:

TNSS scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

应急药物评分

指标类型:

次要指标

Outcome:

RMS scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼部症状总积分

指标类型:

次要指标

Outcome:

TOSS scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

鼻腔灌洗液

组织:

Sample Name:

nasal lavage fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

中央随机系统

Randomization Procedure (please state who generates the random number sequence and by what method):

Central randomization system

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

对患者、评估者和数据分析者实施盲法。

Blinding:

Patients, evaluators, and data analyzers are blinded.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在试验结束、论文完成并发表后,于宁夏医科大学审批后可进行原始数据分享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the trial is over and the paper is completed and published, raw data can be shared after approval by Ningxia Medical University.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-01-09 16:36:53